不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>新品动态>罗氏推出全新药物心肌毒性筛选平台---RTCA Cardio仪器

罗氏推出全新药物心肌毒性筛选平台---RTCA Cardio仪器

互联网2011年2月28日 10:31 点击:1989

瑞士罗氏Roche

 

全新药物心肌毒性筛选平台----罗氏 RTCA Cardio Instrument
 

The xCELLigence System RTCA Cardio Instrument

     秉承不断创新的精神,继罗氏应用科学部连续推出xCELLigence实时细胞分析仪(Real-Time Cell Analyzer,RTCA) SP,RTCA MP和RTCA DP之后,2011年又推出了最新型号的RTCA  Cardio 仪器,使xCELLigence 产品线更加完整。xCELLigence实时细胞分析仪是无需标记、可对细胞进行全程实时监测的新型细胞分析平台,它是目前市场上唯一一台实时无标记的96孔板通量的药物心肌毒性筛选系统,为药物安全性测试和优化提供了崭新的平台。
 
     心脏毒性是药物开发和化合物筛选最需要考虑的因素之一。自1981年以来,已经有至少10几种畅销药物,因在销售过程中发现具有心脏毒性而被撤回,给制药公司带来了巨大经济损失及严重市场影响。同时在药物研发过程中,心脏毒性也成为药物研发失败的主要因素之一。
 
     在这种情况下,心脏毒性的检测已成为药物研发中必不可少的一个环节。但包括膜片钳技术在内的其他技术相对费神费力,操作复杂,不能对心肌细胞实时持续在位检测;hERG钾通道检测会遗漏某些药物非离子通道引发的心脏毒性;动物实验成本较高,无法完成高通量检测。
 
     新型RTCA Cardio仪器将基于阻抗的实时细胞分析技术运用到心脏毒性检测领域,是目前市场上唯一一台96孔通量,实时无标记,可同时进行短期及长期心率失常及心脏毒性药物筛选的细胞分析系统,从而为药物安全检测及优化提供了崭新的平台。
 
     新型RTCA Cardio仪器不但涵盖了RTCA SP/ MP/ DP的所有应用,而且可对药物引发的特异性心肌细胞跳动、细胞活性及生理形态进行短期及长期的检测。具体如下:
 
    ● 心肌细胞搏动检测
    ● 心脏毒性实验
    ● 药物筛选中潜在心脏毒性检测
    ● 化合物介导和细胞介导的细胞毒性
    ● 细胞粘附与细胞伸展
    ● 细胞增殖与细胞分化
    ● 受体介导的信号通路
    ● 病毒介导的细胞病变
    ● 细胞的长期质量控制
    ● 细胞侵入和迁移分析
 
     新型RTCA Cardio仪器进行功能性心肌细胞毒性检测,相比传统方法,可以在全面可控的细胞环境下做持续的短时或长时实验,从而保证实验的持续性、重复性和数据质量;可在早期检测到药物的心脏毒性(引发心律不齐);相比hERG实验,能提供更多有效及重要数据,有效避免假阳性;相对简单的操作,从而能更多使用生理学相关细胞而非基因工程细胞进行实验,提高结果的可信性;通量更大,而且可以长时间实时检测。

Penzberg, Germany, September 28, 2010

Roche's new RTCA Cardio Instrument for label-free functional cardiomyocyte toxicity testing

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it had launched the RTCA Cardio Instrument, the latest member of the xCELLigence product family. The RTCA Cardio Instrument is a medium-throughput cell analyzer that utilizes impedance readings to monitor cardiac beating and cellular events in real time. The instrument features a unique detection rate and frequency measurement concept as well as dedicated software features. Unlike synergistic techniques such as patch clamp, the new system can be used in a fully controlled environment for continuous short-term and long-term experiments, thus increasing the applicable experimental time as well as reproducibility and data quality.

不用本金就能赚钱的方法Cardiotoxicity is one of the most relevant parameters tested in drug development. The RTCA Cardio Instrument is the only 96 well, cardiotoxicity screening system on the market for continuous, real-time, label-free cardiomyocyte beating analysis. The instrument can be used in conjunction with cardiomyocytes derived from human or mouse stem cells for assessing the cardiac safety profile of lead compounds or drug candidates during drug development.

不用本金就能赚钱的方法"There is a clear need and technology gap for cell-based analysis platforms and real-time, label-free technologies," says Ruedi Stoffel, Life Cycle Leader Cellular Analysis at Roche Diagnostics. "The patch clamp techniques currently in use offer only a small glimpse at certain ion channels over the course of a few hours preceding cell death. The RTCA Cardio Instrument provides online beating pattern analysis for Quality Control and standardized conditions, as well as for short-term and long-term experiments."

The xCELLigence system provides a non-invasive, label-free way to continuously monitor cellular parameters such as viability, death, adhesion and proliferation.  The system records the electrical impedance of cells grown on microelectrode arrays integrated into the bottom of each well of an E-Plate 96. Cell-sensor impedance is expressed as the Cell Index (CI), and changes in CI correlate to modifications in cell morphology. Use of the new RTCA Cardio Instrument will be especially high in pharmaceuticals research, pre-clinical safety testing and analysis for cardiac research.

More information please find at .

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

不用本金就能赚钱的方法For life science research only. Not for use in diagnostic procedures.

XCELLIGENCE is a trademark of Roche.
E-PLATE and ACEA BIOSCIENCES are registered trademarks of ACEA Biosciences, Inc. in the US
不用本金就能赚钱的方法 Other brands or product names are trademarks of their respective holders.

(来源: 互联网 )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com

不用本金就能赚钱的方法 BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图